ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

11240	Companies
249354	Keywords
177384	Articles
135173	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/03/2026 at 20:19, 4 months 24 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025

Résultats Financiers Trésorerie Document D’enregistrement Universel OSE Immunotherapeutics Audités
PRESS RELEASE

published on 06/03/2026 at 20:19, 4 months 24 days ago

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics reports full year 2025 audited consolidated financial results and filing of 2025 Universal Registration Document, confirming cash runway with IRIS Financing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
BRIEF

published on 05/28/2026 at 21:09, 4 months 30 days ago

OSE Immunotherapeutics obtient un financement relais flexible en fonds propres

Plan Stratégique Investisseurs Institutionnels Développement Clinique Émission D'actions Financement Flexible
BRIEF

published on 05/28/2026 at 21:09, 4 months 30 days ago

OSE Immunotherapeutics Secures Flexible Bridge Equity Financing

Strategic Plan Clinical Development Institutional Investors Share Issuance Flexible Financing
PRESS RELEASE

published on 05/28/2026 at 21:04, 4 months 30 days ago

OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
OSE Immunotherapeutics lance un financement relais flexible en fonds propres avec IRIS Capital Investment pour un montant pouvant atteindre 19,3 millions d'euros sur 24 mois, prolongeant ainsi son horizon de trésorerie jusqu'à fin décembre 2026

Financement Fonds Propres OSE Immunotherapeutics Horizon De Trésorerie IRIS Capital Investment
PRESS RELEASE

published on 05/28/2026 at 21:04, 4 months 30 days ago

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics announces a flexible bridge equity financing with IRIS Capital Investment to raise €19.3 million, extending cash runway to December 2026 as part of a global financing strategy

OSE Immunotherapeutics Cash Runway Extension Bridge Equity Financing IRIS Capital Investment Global Financing Strategy
BRIEF

published on 05/22/2026 at 07:35, 5 months 6 days ago

OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

Ovarian Cancer Clinical Trial Results OSE Immunotherapeutics Tedopi® TEDOVA Phase 2
BRIEF

published on 05/22/2026 at 07:35, 5 months 6 days ago

OSE Immunotherapeutics annonce des résultats positifs dans un essai clinique sur le cancer de l'ovaire

Résultats Des Essais Cliniques Tedopi® Immunothérapies OSE Cancer De L'ovaire Phase 2 De TEDOVA
PRESS RELEASE

published on 05/22/2026 at 07:30, 5 months 6 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 5 months 28 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026

Accesswire

Published on 10/28/2026 at 08:00, 47 minutes ago

Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 5 hours 52 minutes ago

Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 5 hours 57 minutes ago

Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 9 hours 7 minutes ago

Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 9 hours 22 minutes ago

Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options

View all ACCESSWIRE

EQS Group

Published on 10/28/2026 at 08:05, 42 minutes ago

CookieYes Earns Built for Shopify Badge for Its Cookie Consent App
Published on 10/28/2026 at 08:00, 47 minutes ago

Board Update
Published on 10/28/2026 at 08:00, 47 minutes ago

Coinsilium Group Limited: Portfolio Ventures: Strategic and Commercial Update
Published on 10/28/2026 at 08:00, 47 minutes ago

TRATON GROUP increases unit sales, sales revenue, and adjusted operating result in the first nine months of 2026
Published on 10/28/2026 at 08:00, 47 minutes ago

TAKKT confirms stabilization in the third quarter

Les Echos

Published on 10/28/2026 at 08:00, 47 minutes ago

Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 47 minutes ago

Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 14 hours 47 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 14 hours 47 minutes ago

Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
Published on 10/27/2026 at 17:59, 14 hours 47 minutes ago

Q3 2026 sales

View all LES ECHOS COMFI WIRE